Founders Keepers

Dr Grace Hatton

Want to hear the secrets to startup success, straight from founders' mouths? Interviews with the people behind exciting players in med/bio/healthtech - from initial concept through to investor backing and beyond. Get in touch at hi@founders-keepers.com read less
BusinessBusiness

Episodes

#43 Scott Montgomery - Your handheld biometric smartphone scanner via Advanced Health Intelligence
07-04-2023
#43 Scott Montgomery - Your handheld biometric smartphone scanner via Advanced Health Intelligence
What: This episode is a a follow-on conversation from the Founders Keepers episode with Vlado Bosanac of Advanced Human Imaging, which has since undergone a merger with Wellteq and appointed new Director and CEO, Scott Montgomery. The company has rebranded as ⁠Advanced Health Intelligence⁠ (AHI); a B2B digital health company that offers biometric-enabled and data-driven health solutions – all from a smart phone. The mobile phone-based tech claims to monitor vital signs, calculate body density and identify chronic diseases.  Who: Scott is an established health industry leader with nearly two decades of experience spanning across APAC, Europe and the US, and has co-built two enterprise health companies to trade sale. He has addressed industry-leading topics to audiences at the United Nations on the value of interoperability in healthcare, the role of technology in closing health literacy knowledge gaps, and the potential of biometric triage measurement using smartphones.  We talk about: Healthy scepticism in business, going deep on-device body dimensioning and health analysis, and not giving advice until you’ve been asked for it at least three times.  📝 You can also now read the accompanying "podnotes" to the episode on Substack, where key insights from every conversation will be shared for those who prefer short and snappy takeaways: founderskeepers.substack.com  Find out more:  www.founders-keepers.com  Instagram: @founderskeepers.pod  Twitter: @founders.pod  LinkedIn: https://www.linkedin.com/company/founders-keepers-podcast  Get in touch: hi@founders-keepers.com
#39 Tim Veron - Real-time health tracking with Vively
10-03-2023
#39 Tim Veron - Real-time health tracking with Vively
What: Vively is a software-as-a-service platform supporting people with lifestyle-related diseases: From providing real-time feedback to consumers on diet, exercise, sleep and stress to integrating continuous glucose monitors (CGMs) and wearables for real-time data analytics about how users’ lifestyle impacts their health. The organisation collaborates with a team of leading integrative doctors, behavioural scientists and holistic health practitioners to create and combine digital therapeutic programs with on-demand coaching and health analytics, and recently secured AUS$1.5 million in pre-seed funding to support their expansion.  Who: Tim is a serial entrepreneur with a background in venture capital who prior to co-founding Vively had invested and founded various different startups active across Asia and Australasia.  We talk about: Tim's obsession with entrepreneurship from a young age; finding a solution to medical conditions brought on by lifestyle choices; and how building his own product at Vively identified a potentially serious health complaint in Tim despite his triathlete background.  📝 You can also now read the accompanying "podnotes" to the episode on Substack, where key insights from every conversation will be shared for those who prefer short and snappy takeaways: founderskeepers.substack.com Find out more: www.founders-keepers.com Instagram: @founderskeepers.pod Twitter: @founders.pod LinkedIn: https://www.linkedin.com/company/founders-keepers-podcast Get in touch: hi@founders-keepers.com
#36 Dr Sharon Rogers - Finding a cure for Alzheimer's Disease with AmyriAD
17-02-2023
#36 Dr Sharon Rogers - Finding a cure for Alzheimer's Disease with AmyriAD
AmyriAD is an LA-based clinical-stage biotech company working to advance effective therapies for the treatment of Alzheimer's Disease, bringing together decades of experience with the singular goal of easing the devastation it causes. The Company's lead drug candidate, AD101, is a small molecule under development for the treatment of Alzheimer's Disease and will be entering Phase 3 clinical trials later this year in 2023 following successful randomised double-blind placebo-controlled trials where it has been administered as an add-on to stable donepezil (Aricept®) therapy. Sharon was the global lead and development strategist for the highly successful Alzheimer’s Disease treatment, Aricept® (donepezil). From an incredible and widely varied career that started in figure skating and restaurant ownership, she has worked in high-ranking positions for several decades in the pharmaceutical industry and more recently in the startup space, leading the VC-backed AmyriAD. We talk about one of her earliest ventures delivering food to half-naked frat boys, her expat life in Japan, and why she is so passionate about advancing a cure for Alzheimer’s Disease. You can find out more about AmyriAD in the following ways: Website: https://amyriadtherapeutics.com/ Twitter: https://twitter.com/AmyriAD_Tx LinkedIn: https://www.linkedin.com/company/amyriad-therapeutics/ Find us on: www.founders-keepers.com and www.founderskeepers.substack.com Instagram: @founderskeepers.pod Twitter: @founders.pod LinkedIn: https://www.linkedin.com/company/founders-keepers-podcast Get in touch: hi@founders-keepers.com
#33 Dr Seth Lederman - Vaccines and drug repurposing in biodefense and PTSD with Tonix Pharmaceuticals
03-02-2023
#33 Dr Seth Lederman - Vaccines and drug repurposing in biodefense and PTSD with Tonix Pharmaceuticals
Tonix Pharmaceuticals is a pharmaceutical company based in New Jersey focused on repurposing drugs for neurological conditions and developing vaccines for COVID-19, smallpox and other biodefense projects. More recently, the FDA awarded one of its drug candidates, TNX -102 SL, with breakthrough therapy designation for the treatment of post-traumatic stress disorder following studies in the US military. Seth is an enormously accomplished physician, scientist and entrepreneur. In particular prior to co-founding Tonix, where he is now the current President and Chairman, he worked as an assistant professor at Columbia University on the team that discovered the CD40-Ligand (CD154) and elucidated the molecular basis of T cell helper function. This discovery alone has since led to the development of treatment candidates for numerous autoimmune diseases as well as for organ transplant rejection. In this episode, we cover the biotech revolution in vaccine development, the need for versatility in hiring, and inherent difficulty of “doing science” in the real world. You can find out more about Tonix Pharmaceuticals in the following ways: Website: https://www.tonixpharma.com/ Twitter: https://twitter.com/TONIXPharma LinkedIn: https://www.linkedin.com/company/tonix-pharmaceuticals/ Find us on: www.founders-keepers.com Instagram: @founderskeepers.pod Twitter: @founders.pod LinkedIn: https://www.linkedin.com/company/founders-keepers-podcast Get in touch: hi@founders-keepers.com
#32 Dr Philip Kantoff - Radiopharmaceutical cancer targeting with Convergent Therapeutics
27-01-2023
#32 Dr Philip Kantoff - Radiopharmaceutical cancer targeting with Convergent Therapeutics
Convergent Therapeutics is a clinical-stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy that has been licensed to Convergent by Cornell University (USA).  If FDA-approved, its flagship therapeutic would be the first antibody approved to direct a radioisotope to prostate cancer. Dr Kantoff is a board-certified physician in internal medicine and medical oncology; a member of numerous professional societies and editorial boards; author of more than 500 articles and books; and has lectured throughout the world on the topic of cancer treatments. He has been honored with the Harvard Medical School Kantoff-Sang Lectureship Award, and recognized with the first Prostate Cancer Foundation Mentor of Excellence Award.  In this episode, we cover raising money in difficult climates, the important “engine of discovery” that is the biotech industry, and dealing with the unpredictable both as a physician and a company CEO. You can find out more about  Convergent Therapeutics in the following ways: Website: https://convergentrx.com/ Twitter: https://twitter.com/ConvergentRx LinkedIn: https://www.linkedin.com/company/convergent-therapeutics/ Find us on: www.founders-keepers.com Instagram: @founderskeepers.pod Twitter: @founders.pod LinkedIn: https://www.linkedin.com/company/founders-keepers-podcast Get in touch: hi@founders-keepers.com
#30 Pete O'Heeron - Regenerative medicine and treating chronic disease with FibroBiologics
13-01-2023
#30 Pete O'Heeron - Regenerative medicine and treating chronic disease with FibroBiologics
Kicking off the first episode of Founders Keepers of 2023 is Pete O’Heeron - the Founder and CEO of FibroBiologics. FibroBiologics is a clinical-stage regenerative medicine company based in Houston, Texas, developing a pipeline of treatments for chronic diseases using fibroblast cells. They hold over 150 US and international issued patents and patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution, and cancer. Pete is a seasoned leader in his field with over 25 years of experience in medical technology and biotech development. Prior to founding FibroBiologics/FibroGenesis, LLC, he founded an operational investment group, Advanced Medical Technologies, LLC, that identified early-stage opportunities in the medical field with strong intellectual property potential. He also founded NeoSurg Technologies, sold to Cooper Surgical in 2006. In this episode, we cover having a high tolerance for the word “no”, working without a proverbial safety net, and revolutionising the regenerative medicine world. You can find out more about FibroBiologics in the following ways: Website: https://fibrobiologics.com/ LinkedIn: https://www.linkedin.com/company/fibrobiologics/ Find us on: www.founders-keepers.com Instagram: @founderskeepers.pod Twitter: @founders.pod LinkedIn: https://www.linkedin.com/company/founders-keepers-podcast Get in touch: hi@founders-keepers.com
#27 Mohamed Taha - AI-powered sperm analysis with Mojo Fertility
25-11-2022
#27 Mohamed Taha - AI-powered sperm analysis with Mojo Fertility
Launched in 2017, Mojo is an AI-powered fertility care platform that helps people to understand, test, and improve their fertility in preparation for starting a family. Having raised a total of US$5.5 million over 2 funding rounds, Mojo's main offering is an at-home fertility testing kit that provides detailed results to users within 48h of sampling, alongside on-demand consultations with UK-leading fertility specialists. The company achieves rapid test turnaround through their WHO-complaint, proprietary, in-house built AI-powered microscope that revolutionises both accessibility to and the level of standard in sperm analysis. , and has been profiled in Wired magazine as well as multiple other media outlets. Mo has a PhD in materials engineering and nanotechnology, and set up Mojo in 2017 along with three other founders to apply his research skillset to a real-world problem. In this episode we cover his personal health reasons behind starting Mojo, shining the light on male fertility issues, and how “failing a lot” has helped his entrepreneurial journey. You can find out more about Mojo in the following ways:  Website: https://mymojo.ai/ Instagram: https://www.instagram.com/mymojo.ai/  Twitter: https://twitter.com/MyMojoAI LinkedIn: https://www.linkedin.com/company/my-mojo/ Find us on:  www.founders-keepers.com  Instagram: @founderskeepers.pod  Twitter: @founders.pod  LinkedIn: https://www.linkedin.com/company/founders-keepers-podcast  Get in touch: hi@founders-keepers.com